Suchen
Ascendis Pharma A/S
ASNDZur Watchlist hinzufügen
251.270USD
-1.730-0.68%
Handelsschluss 10-30 16:00（ET）
15.20BMarktkapitalisierung
36.19KGV TTM
Über Ascendis Pharma A/S Unternehmen
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Ascendis Pharma A/S Profil
BörsenkürzelASND
Name des UnternehmensAscendis Pharma A/S
IPO-datumJan 28, 2015
CEOMoller Mikkelsen (Jan)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeJan 28
AddresseTuborg Boulevard 12
StadtHELLERUP
BörseNASDAQ OMX - NASDAQ BASIC
LandDenmark
Postleitzahl2900
Telefon4570222244
Websitehttps://ascendispharma.dk/
BörsenkürzelASND
IPO-datumJan 28, 2015
CEOMoller Mikkelsen (Jan)
Führungskräfte von Ascendis Pharma A/S
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Dr. Aimee Shu, M.D.
Dr. Aimee Shu, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
1.92K
--
Dr. Aimee Shu, M.D.
Dr. Aimee Shu, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
1.92K
--
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.43K
-9.72%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Ascendis Pharma A/S?
Die fünf größten Anteilseigner von Ascendis Pharma A/S sind: Mr. Flemming Steen Jensen
Wie viele Institutionen halten Anteile an Ascendis Pharma A/S (ASND)?
Mit Stand vom 2026Q1 halten 582 Institutionen Anteile an Ascendis Pharma A/S, mit einem Gesamtmarktwert von etwa 69.20M, was 111.42% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1676383.00 gestiegen.
Was ist die größte Einnahmequelle von Ascendis Pharma A/S?
Am 2026Q1 erzielte das Geschäft mit Commercial sale of products für Ascendis Pharma A/S den höchsten Umsatz in Höhe von 314.91M, was 92.82% des Gesamtumsatzes entspricht.